Evaluation of e-cadherin and vimentin expression for different grades of oral epithelial dysplasia and oral squamous cell carcinoma – An immunohistochemical study

Nagireddla Puneeta¹, Tummidi Santosh², Isha Mishra¹, Pravin Gaikwad¹, Anshuta Sahu¹

¹Department of Oral Pathology, Maitri College of Dentistry and Research Centre, Durg, Chhattisgarh, ²Department of Pathology and Lab Medicine, AIIMS, Kalyani, India

Abstract

Background: Oral cancer is the 11th common cancer in the world and ranks 6th globally in deaths. The incidence of oral cancer in India accounts for approximately 30%–40% of all cancers.

Aims and Objective: The present study was undertaken to evaluate the expression of Vimentin and E-cadherin in different grades of oral epithelial dysplasias (OEDs) and oral squamous cell carcinoma (OSCC).

Materials and Methods: Biopsies/blocks of oral cavity lesions were retrieved from the archives of the department. Normal oral mucosa (5 cases), oral epithelial dysplastic (60 cases) and different grades of OSCC (60 cases) evaluated by hematoxylin and eosin sections. Immunohistochemical analysis was done on the blocks and expression of E-cadherin and Vimentin was recorded.

Results: Our study included various grades of OED, OSCC and normal mucosa as control cases. The mean age of OED and OSCC was 49 and 56 years, respectively, with male predominance. Tobacco habit was present in approximately 90% cases, and buccal mucosa was the most commonly involved site in oral cavity with whitish patch and ulceroproliferative lesions being the common clinical presentations respectively. In OED, downregulation and altered localization of e-cadherin (81.6%) and increased expression of vimentin (52.3%) along with their concurrent increase in the stroma represent epithelial mesenchymal transition. In OSCC, reduction in expression (<50%) for e-cadherin (56.6%) with altered localization for e-cadherin was seen in 88.3% of OSCC along with neoexpression of vimentin in the epithelial cells was seen in 68.3% suggestive of mesenchymal phenotypic modification \((P = 0.05)\).

Conclusion: It is very crucial to evaluate the invasiveness of dysplasia and tumor with specific molecular biomarker that may help in early prediction of malignancy and also guide in deciding best treatment strategy for established cases of malignancy.

Keywords: Buccal mucosa, e-cadherin, immunohistochemistry, oral epithelial dysplasia, squamous cell carcinoma, vimentin

INTRODUCTION

Oral squamous cell carcinoma (OSCC) is the most frequent malignancy of oral cavity ranked the 6th most common cancer worldwide causing deaths.\(^{[1,2]}\) Its association with chronic tobacco/areca nut use is particularly more

Access this article online

Quick Response Code:

Website: www.jomfp.in

DOI: 10.4103/jomfp.JOMFP_166_20

How to cite this article: Puneeta N, Santosh T, Mishra I, Gaikwad P, Sahu A. Evaluation of e-cadherin and vimentin expression for different grades of oral epithelial dysplasia and oral squamous cell carcinoma – An immunohistochemical study. J Oral Maxillofac Patho 2022;26:285-6.
prevalent in the Indian subcontinent.[3] Despite the advent of newer diagnostic and therapeutic approaches, the overall 5-year survival rate is poor (<50%) making it a global health problem.[4,5] The management is often associated with severe functional and cosmetic defects leading to substantial morbidity.[4]

Progression of these oral potentially malignant disorders to carcinoma is multi-stage process wherein the normal mucosa on exposure to tobacco/areca nut can progress to the development of premalignant lesions, i.e., oral leukoplakia, erythroplakia and oral submucous fibrosis (OSMF) which can further proceed to malignancy.[2] OSCCs have a propensity to metastasize to the loco-regional lymph nodes as well as to distant sites resulting in considerable disability and mortality.[6] Despite the fact that the mucosa may appear clinically normal, there may be changes at the molecular level predisposing the development of potentially malignant lesions and OSCC. Currently, histological grade is the best predictor for progression of premalignancy to malignancy and to define the aggressiveness of cancer.[7] Markers of epithelial mesenchymal transition (EMT) can help in early detection and management of OSCC in the premalignant stage, and can considerably improve the cancer free survival and quality of life of the patients.[8]

**Aims and objectives**
The aim and objective were to evaluate the expression of e-cadherin and vimentin in different grades of oral epithelial dysplasia (OED) and OSCCs. The correlation of e-cadherin and vimentin between normal mucosa, dysplasia, OSCCs with vimentin and e-cadherin was done.

**MATERIALS AND METHODS**

**Patients and specimens**
A total of 125 cases were included in our study, and the blocks for the period of 2 years (2017–2019) were retrieved from department archives of our institute. The cases were biopsies of normal buccal mucosa (5 cases), OED (mild, moderate, severe dysplasia 20 cases each), and OSCC (well, moderate and poorly differentiated 20 cases each). None of the patients had received any tumor-specific therapy (chemotherapy or radiotherapy). The study was approved by the institutional ethical committee.

**Histopathology diagnosis**
Tissues blocks were retrieved from department repository. Sections were cut at 4 µm and stained with H and E. Histological grading was done on hematoxylin and eosin-stained sections according to the revised criteria given by the World Health Organization 2017 for OED, whereas grading of squamous cell carcinoma was based on Bryne’s invasive front grading system.[9]

**Immunohistochemistry**
The tissue sections (4 µm) were cut from representative paraffin blocks collected in pre-coated poly-l-lysine slides and were then deparaffinized in xylene and rehydrated in graded alcohol. Endogenous peroxidase was blocked using 3% hydrogen peroxide. Antigen retrieval was done by conventional microwave method in 10 mMol/l sodium citrate retrieval buffer (pH 6.0) for 10-, 10- and 5-min slots. The sections were then incubated with following steps-super enhancer 20 min, 3 times wash with buffer solution, primary antibodies 45 min (antibodies used were e-cadherin, clone A36-Mouse monoclonal IgG1, Biogenex Code No: AM390-5M and Vimentin, clone V9-Mouse Monoclonal IgG, Biogenex Code No: AM074-5M ready to use) 3 times wash with buffer solution, secondary antibody kit (histidine-rich protein) for 20 min, 3 times wash with buffer solution, DAB stain for 1 min and 3 times wash with buffer solution, followed by counterstain with hematoxylin.

**Evaluation of immunoreactivity**
IHC stained slides were semi-qualitatively evaluated on the basis of staining of epithelial cells or mesenchymal. The antibodies expression was studied using the following four parameters:
1. Intensity
2. Location
3. Percentage positivity
4. Extent.

The expression of the epithelial proteins like e-cadherin was evaluated only in the epithelial cells, while the expression of the mesenchymal proteins like vimentin was evaluated both in the cells of the epithelium and the connective tissue. The parameters 1st, 2nd and 3rd criteria were same for E-cadherin and vimentin while the 4th parameter criteria varied based on the antibody and its expression in epithelium or connective tissue.

**Statistical analysis**
The correlation between clinicopathological parameters and e-cadherin and vimentin expression was analyzed using the Chi-square test and Fisher’s exact test. A P < 0.05 was considered statistically significant.

**RESULTS**

**Clinicopathological features**
The study population was taken from the archives of the department records. A total of 125 cases included...
5 normal cases, 60 OED and 60 OSCCs. OED was predominantly in 4th decade age group (48.3% cases) with a mean age being 49.05 years. On the contrary, OSCC was more predominant in the age 5th to 6th decade (43.4% cases) with a mean age of 56 years.

OED and OSCC were more predominant among the males with a ratio of 2:1 and 3:1, respectively. History of tobacco consumption was present in OED and OSCC in 93% and 83%, respectively, however the details of smoking history/tobacco type and number of pack consumption/year was not available in the retrieved records. Buccal mucosa was the most common site to be involved in all the study groups (63% cases in OED and 43% cases in OSCC) followed by tongue in OED, retromolar trigone in OSCC. The various other sites involved in OED and OSCC included alveolus, tongue, gingiva, lip, floor of the mouth, angle of mouth, palate as well as multiple site involvement. Clinical presentation was whitish patch over buccal mucosa in 42% cases, whereas ulceroproliferative lesion was noted in only 28% cases of OED whereas in OSCC 83% cases.
Expression of e-cadherin in oral epithelial dysplasia and oral squamous cell carcinoma patients

E-cadherin expression was predominantly intense for normal mucosa (100%) [Figure 1a-c]. We had a progressive reduction in the intensity of e-cadherin expression over OED grades: mild (90%), moderate (85%) and severe OED (70%) [Figure 2a-c, 3a-c, 4a-c]. The reduction in the intensity of staining pattern was observed with the increasing grades of OSCC well (60%), moderate (45%) and poorly (25%). \( P \approx 0.05 \) was statistically significant.

The normal mucosa was showing membranous pattern of e-cadherin expression (100%). There was a progressive cytoplasmic shift as evident with increasing grades of OED, i.e., mild (5%), moderate (15%) and severe OED (60%) which was statistically significant (\( P = 0.001 \)). Cytoplasmic localization was prominently increasing in the carcinoma group with well differentiated 70%, moderately differentiated 95% and all the poorly differentiated SCCs showing a cytoplasmic location (100%) and statistically significant (\( P = 0.008 \)) [Figure 5a-c, 6a-c, 7a-c].

E-cadherin expression was noted predominantly in the basal/parabasal layer (80%) and spinous layer (20%) of normal mucoa. A progressive involvement of all layers was seen in the OED group with 5% of mild OED, 10% of moderate and 70% of severe OED showing expression till the surface layers (\( P < 0.001 \)) which was statistically significant. This pattern of involvement could not be noted among the OSCC due to lack of intact epithelium in the malignant group.

Vimentin expression in oral epithelial dysplasia and oral squamous cell carcinoma patients

The normal mucosa specimens did not show vimentin expression in the epithelium [Figure 1d]. Vimentin positivity was low in mild OED (45%) while high expression was evident in 15% of moderate and 40% of severe OED, which was statistically significant (\( P = 0.02 \)) [Figure 2d, 3d, 4d]. A progressive high expression (>50%) was evidenced with poor histologic grades, i.e., well-differentiated squamous cell carcinoma (WDSCC) (10%), moderately differentiated squamous cell carcinoma (MDSCC) (20%) and poorly differentiated squamous cell carcinoma (PDSCC) (50%) which was statistically significant (\( P = 0.03 \)). An intense expression was associated with increased grade of OED, i.e., mild (20%), moderate (30%) and severe (60%) so was in OSCC though more pronounced, i.e., WDSCC (40%), MDSCC (60%), PDSCC (85%) which was statistically significant (\( P < 0.05 \)). All cases positive for vimentin in the epithelium were seen to be localized in the cytoplasm.

The connective tissue expression of vimentin was seen in all cases of normal mucosa [Figure 1d]. In 60% of cases, it was mild whereas, 40% cases showed intense expression (100%) located in the cytoplasm. A progressive increase in intensity was observed with grades of OED, i.e., intense expression in mild (65%), moderate (70%) and severe (80%). Similarly, WDSCC showed intense expression in 80% of cases while MDSCC and PDSCC both showed 85% and 95% intense expression, respectively.
There are molecular studies that have explored a number of genes being amplified, altered, dysregulated in expression or deleted in head-and-neck tumorigenesis. The quench for early detection of the lesion and progression is necessary as it increases the chances of favorable treatment outcome and better prognosis.\textsuperscript{[2,12,13]}

Dysplasia presence and severity in a potentially malignant oral lesion is currently the standard in predicting the risk for malignant transformation.\textsuperscript{[14]} It has been observed that precancerous lesions with epithelial dysplasia progress to cancer more readily. The chances of malignant transformation in nondysplastic leucoplakia lack evidence currently considering the differences in the behavior or risk of malignant transformation.\textsuperscript{[15,16]}

Malignant transformation in various carcinomas is associated with the loss of epithelial differentiation and a gain in a mesenchymal phenotype, which has been described in events associated with embryogenesis, healing and metastasis.\textsuperscript{[14,17]} Epithelial to mesenchymal transition (EMT) may be a predictor of OSCC progression and prognosis as suggested in recent studies.\textsuperscript{[18,19]} The concept of EMT was first proposed by Greenberg et al. Their features are noted in both OSCC progression and OED. These changes can be seen in the development of OSCC; the identification of genes or their products that play a role in the transition process may be the potential biomarkers of malignant transformation.\textsuperscript{[18,21]}

E-cadherin is a calcium dependent cell surface adhesion molecule with 120-kDa, responsible for the control of cell motility in embryogenesis or tissue healing. Downregulation of e-cadherin allows migration of the regenerating epithelium over area of ulceration.\textsuperscript{[22,23]} Hence, the role of e-cadherin in control of cell motility has led to the suggestion that it is an “invasion suppressor” molecule responsible for various carcinomas of head-and-neck region, prostrate, esophagus, stomach, pancreas and uterine cervix.\textsuperscript{[14,22,26]} E-cadherin reduced expression has correlated with high proliferation, aggressive behavior, invasion, metastasis and poor prognosis of cancer.\textsuperscript{[2,27]} Hence, it indicates the prognostic significance of e-cadherin during therapeutic intervention.

Vimentin is a type III intermediate filament protein of mesenchymal cells having a molecular weight 54 kDa. Vimentin was previously thought to be only a structural protein.\textsuperscript{[3,28]} However, recent evidence suggests the role in regulation of various cellular functions including migration, cell signaling, cell attachment and tumor metastases.\textsuperscript{[29]} Its expression correlates with poor prognosis in various carcinomas including OSCC.\textsuperscript{[3,29]} The proposed location
of molecular markers specifically in the invasive fronts of tumor has more prognostic significance rather than their expression levels. These reports together indicate that aberrant expression of vimentin is associated with tumor invasion and metastases. However, there are no reports available regarding its expression in precancerous lesions except for one who have demonstrated its expression in the hyperkeratotic lesions of oral mucosa.

In the present study, we had focused in the identification of e-cadherin and vimentin markers role in early stages of oral tumor development and to further determine clinical significance of its expression for the prediction of high-risk oral lesions. E-cadherin expression in low-grade OED was similar to the control normal group of patients. A greater loss of e-cadherin expression with shift in localization to cytoplasmic was noted with increasing grades of OED and to OSCC. A shift from basal and parabasal intercellular expression of e-cadherin to the upper 1/3 layers was noted in grades of OED, possibility due to delayed desquamation and immature cells. However, this parameter could not be applied to OSCC due to lack of the intact epithelium. Similar were the observations done by Yogesh et al., Kaur et al., Sridevi et al., Zhou et al., and Akhtar et al.

Vimentin expression increased with the progression of OED and into OSCC. Myong had observed no immunoreactivity for vimentin in normal buccal mucosa. Araujo et al. had a vimentin positivity in cells of histologically high grade of tumor and was associated with poor outcome on patient treatment.

Myong has reported a statistically significant inverse correlation between e-cadherin and vimentin immunoreactivity, with \( P < 0.001 \) in their study on 119 cases, a finding discordant with our study. Carcinoma \( \text{in situ} \) lesions had 8.8% immunoreactivity, whereas microinvasive and invasive carcinomas were having higher vimentin expression in approximately 53.0% and 67.0% cases, respectively, findings discordant with our study. Hence, a significantly increased vimentin expression can be a target for EMT marker in the progression of premalignant/carcinoma \( \text{in situ} \) to microinvasive or invasive squamous cell carcinoma.

CONCLUSION

With the limited number of cases, we were having the findings of variation in expression of e-cadherin and vimentin with various grades of OED and OSCCs in comparison to normal mucosa. Long-term follow-up will be required for patient’s prognosis and prognosticate the malignant potential of premalignant lesions.

Abbreviations:

EMT: Epithelial mesenchymal transition, H&E: Hematoxylin and eosin, HRP: Histidine Rich protein, IHC: Immunohistochemistry, OED: Oral Epithelial Dysplasia, OSCC: Oral Squamous Cell Carcinoma, OSMF: Oral Sub Mucosal Fibrosis, WHO - World Health Organization.

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee. IEC approval Number-MCDRC/2017/10081.

Consent for publication

Written consent for publication and any additional related information was taken from the patient involved in the study.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Solan P, Gale N, Hunter K, Lingen M, Nylander K, Reibel J, et al. Malignant surface epithelial tumours. In: El-Naggar AK, Chan JK, Grandis JR, Takata T, Slootweg PJ, editors. WHO Classification of Head and Neck Tumours. 4th ed. Switzerland: WHO Press; 2017. p. 105-16.
2. Sridevi U, Jain A, Nagalaxmi V, Kumar UV, Goyal S. Expression of E-cadherin in normal oral mucosa, in oral precancerous lesions and in oral carcinomas. Eur J Dent 2015;9:364-72.
3. Sawant SS, Vaidya Mr, Chaukar DA, Alam H, Dmello C, Gangadaran P, et al. Clinical significance of aberrant vimentin expression in oral premalignant lesions and carcinomas. Oral Dis 2014;20:453-65.
4. Gupta N, Gupta R, Acharya AK, Pathi B, Goud V, Reddy S, et al. Changing trends in oral cancer-A global scenario. Nepal J Epidemiol 2016;6:613-9.
5. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
6. Riquelme I, Roa JC. Activated status of Hedgehog pathway in oral squamous cell carcinoma (OSCC): The door is still open. Transl Cancer Res 2016;5:14-6.
7. Akhtar K, Ara A, Siddiqui SA, Sherwani RK. Transition of immunohistochemical expression of E-cadherin and vimentin from premalignant to malignant lesions of oral cavity and oropharynx. Oman Med J 2016;31:165-9.
8. Balasundaram P, Singh MK, Dinda AK, Thakar A, Yadav R. Study of β-catenin, E-cadherin and vimentin in oral squamous cell carcinoma with and without lymph node metastases. Diagn Pathol 2014;9:145.
9. Das RK, Pal M, Barui A, Paul RR, Chakraborty C, Ray AK, et al. Assessment of malignant potential of oral submucous fibrosis through evaluation of p63, E-cadherin and CD105 expression. J Clin Pathol 2010;63:894-9.
et al. E-cadherin and Vimentin expression in OEDs and OSCCs- An Immunohistochemical study

10. Narayan SR. Oral cancer in India: An epidemiologic and clinical review. Oral Surg Oral Med Oral Pathol 1996;82:350-6.
11. Wagner VP, Webber LP, Curra M, Klein IP, Meurer L, Carrad VC, Martins MD. Bryne's grading system predicts poor disease-specific survival of oral squamous cell carcinoma: a comparative study among different histologic grading systems. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;123:688-96.
12. Jankowski JA, Bruton R, Shepherd N, Sanders SA. Cadherin and catenin biology represent a global mechanism for epithelial cancer mechanism. J Clin Pathol Mol Pathol 1997;50:289-90.
13. Wijnhoven BP, Djinjens WN, Pinigatti M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 2000;87:992-1005.
14. von Zeidler SY, de Souza Botelho T, Mendonça EF, Batista AC. E-cadherin as a potential biomarker of malignant transformation in oral leukoplakia: A retrospective cohort study. BMC Cancer 2014;14:972.
15. Liu W, Wang YF, Zhou HW, Shi P, Zhou ZT, Tang GY. Malignant transformation of oral leukoplakia: A retrospective cohort study of 218 Chinese patients. BMC Cancer 2010;10:685.
16. Lee JJ, Hong WK, Hittelman WN, Mao I, Lotan R, Shin DM, et al. Predicting cancer development in oral leukoplakia: Ten years of translational research. Clin Cancer Res 2006;12:702-10.
17. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005;17:548-58.
18. Chow SY, Abdul Majed A, Dalley AJ, Chan A, Stein S, Farah CS. Epithelial to mesenchymal transition (EMT) biomarkers – E-cadherin, beta-catenin, APC and Vimentin – In oral squamous cell carcinogenesis and transformation. Oral Oncol 2012;48:997-1006.
19. Theveneau E, Mayor R. Cadherins in collective cell migration of mesenchymal cells. Curr Opin Cell Biol 2012;24:677-84.
20. Greenburg G, Hay ED. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol 1982;95:333-9.
21. Smith J, Ratray T, McConkey C, Hellwell T, Mehana H. Biomarkers in dysplasia of the oral cavity: A systematic review. Oral Oncol 2009;45:647-53.
22. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991;113:173-85.
23. Liu JK, Jiang XY, Zhou XX, Wang DM, Song XL, Jiang HB. Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: Correlation with the clinicopathological features and patient outcome. Mod Pathol 2010;23:213-24.
24. Zhang W, Alt-Holland A, Margulis A, Shamis Y, Fusedig NE, Rodeck U, et al. E-cadherin loss promotes the initiation of squamous cell carcinoma invasion through modulation of integrin-mediated adhesion. J Cell Sci 2006;119:283-91.
25. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004;4:118-32.
26. van der Velden LA, Manji JJ, Ramakers FC, Kuipers W. Expression of intermediate filament proteins in benign lesions of the oral mucosa. Eur Arch Otorhinolaryngol 1999;256:514-9.
27. Lipponen P, Saarelainen E, Ji H, Aaltomaa S, Syrjänen K. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer. J Pathol 1994;174:101-9.
28. Ivaska J, Pallari HM, Nevo J, Eriksson JE. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res 2007;313:2050-62.
29. Akhtar K, Ara S, Siddiqui SA, Shervani RK. Diagnostic and prognostic significance of E-Cadherin and vimentin in oral cancer metastasis. Ann Pathol Lab Med 2016;03:A8-13.
30. Schliepke H. Prognostic relevance of molecular markers of oral cancer – A review. Int J Oral Maxillofac Surg 2003;32:233-45.
31. Velden LA, Schaaftma EH, Manji JJ, Ramakers FC, Kuipers W. Expression of cytokeratin subtypes and vimentin in squamous cell carcinoma of the floor of the mouth and the mobile tongue. Otorhinolaryngol Nova 2001;11:186-92.
32. Yogesh T, Narayan T, Shreedhar B, Shashidara R, Leekumahathy, The expression of E-cadherin and cathepsin-D in normal oral mucosa, oral epithelial dysplasia and oral squamous cell carcinoma: A comparative analysis between immunohistochemistry and routine histopathology. J Oral Maxillofac Surg 2011;15:288-94.
33. Kaur G, Carnelio S, Rao N, Rao L. Expression of E-cadherin in primary oral squamous cell carcinoma and metastatic lymph nodes: An immunohistochemical study. Indian J Dent Res 2009;20:71-6.
34. Zhou J, Tao D, Xu Q, Gao Z, Tang D. Expression of E-cadherin and vimentin in oral squamous cell carcinoma. Int J Clin Exp Pathol 2015;8:3150-4.
35. Myong NH. Loss of E-cadherin and acquisition of vimentin in epithelial-mesenchymal transition are noble indicators of uterine cervix cancer progression. Korean J Pathol 2012;46:341-8.
36. de Araujo VC, Pinto Júnior DS, de Sousa SO, Nunes FD, de Araujo NS. Vimentin in oral squamous cell carcinoma. Eur Arch Otorhinolaryngol 1993;250:105-9.
37. Nayak MT, Singh A, Desai RS, Vanaki SS. Immunohistochemical analysis of vimentin in oral submucous fibrosis. J Cancer Epidemiol 2013;2013:549041.
38. Nijkamp MM, Span PN, Hoogsteen JJ, van der Kogel AJ, Kaanders JH, Buusink J. Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiother Oncol 2011;99:344-8.